Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Novo Nordisk Opens Second R&D Center in Beijing

publication date: Sep 24, 2012
Novo Nordisk, the Danish drug company known for its diabetes focus, officially opened a new $100 million R&D center in Beijing’s Zhongguancun Life Science Park, near the company’s existing facility. The new center will allow the company to increase R&D staffing in China from 130 to 200 in the immediate future. With the increased capacity, the center is now able to conduct the full range of protein research in China, according to Novo Nordisk. More details....

Stock Symbol: (NYSE: NVO)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital